Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Arrowhead Subsidiary Licenses Technology to Incorporate Carbon Nanotubes into Miniaturized Medical Devices for the Treatment of Cardiovascular Disease

Abstract:
Nanotechnology Holds Promise as Next Frontier in Vascular Intervention

Arrowhead Subsidiary Licenses Technology to Incorporate Carbon Nanotubes into Miniaturized Medical Devices for the Treatment of Cardiovascular Disease

PASADENA, CA and CHARLESTON, WV | Posted on August 3rd, 2007

Arrowhead Research Corporation (NASDAQ:ARWR) and Paragon Intellectual Properties, LCC announced today that Arrowhead's majority-owned subsidiary, Unidym Inc., has signed an exclusive license agreement with Paragon's majority-owned subsidiary, Nanotech Catheter Solutions, LLC (NCS). NCS will use Unidym's carbon nanotube technology in the development of medical devices for the treatment of cardiovascular disease. Under the terms of the agreement, Unidym will receive a 20 percent equity stake in NCS, and the parties will negotiate a supply agreement or royalty.

"We are pleased that our agreement with NCS could lead to improvements in technology to treat the millions of people around the world with cardiovascular disease," stated Art Swift, Unidym's CEO. "This agreement marks the launch of Unidym's licensing program. Our goal is to license our intellectual property and/or supply nanotubes to third parties commercializing products incorporating carbon nanotubes outside of our focus of electronics. We intend to replicate this model in other areas such as nanotube-based therapeutics, diagnostics, field emission displays, nonvolatile memory, and composite materials."

"We are thrilled about the opportunity to play a leading role in this exciting area of advanced technology," said Mark C. Bates, M.D., a leading interventional cardiologist and founder of the CAMC Vascular Center of Excellence in Charleston, West Virginia, and CEO of Paragon Intellectual Properties (the parent of NCS) and NCS. "We firmly believe that the application of nanotechnology to interventional devices such as catheters and stents could change the rules under which device designers operate, allowing them to implement improvements not previously deemed possible. This agreement with Unidym gives NCS critical intellectual property in this promising field."

####

About Arrowhead Research Corporation
Arrowhead Research Corporation ( http://www.arrowheadresearch.com ) is a publicly traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority-owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics, and compound semiconductor materials.

About Unidym, Inc.

Unidym ( http://www.unidym.com ) is a leader in the manufacture and application of carbon nanotubes (CNTs), a novel material with extraordinary electrical, thermal, and mechanical properties. Unidym provides bulk materials, CNT-enabled products, and intellectual property to a wide range of customers and business partners. As a result of its recent merger with CNI, Unidym possesses a foundational patent portfolio that covers nearly every aspect of CNT manufacturing and processing as well as multiple product applications.

Unidym is focused on the electronics industry where its initial products include transparent electrodes for touch screens, flat panel displays, solar cells, and solid state lighting; electrodes for fuel cells; and thin film transistors for printable electronics. Unidym is also pursuing an aggressive, cross-industry partnership strategy to capture value from the wide ranging uses of CNTs. Unidym’s licensing program, technical expertise, and manufacturing facilities can enable partners to rapidly develop CNT solutions for their specific applications.

About Paragon Intellectual Properties

Paragon Intellectual Properties, LLC was founded in 2004 by Mark C. Bates, M.D., to develop innovative breakthrough solutions to complex medical problems. Headquartered in Charleston, West Virginia, with research and development in Carlsbad, California, Paragon has assembled a team of like-minded clinicians, scientists, engineers, and business leaders. Paragon’s seven subsidiaries (Apollo Therapeutics, LLC; Biflex Hybrid Stent Systems, LLC; Global Stem Cell Solutions, LLC; Nanotech Catheter Solutions, LLC; Renal Protection Solutions, LLC; Spinal Cord Injury Solutions, LLC; and Temporary Intravascular Drug Delivery Systems, LLC) hold fifty-nine issued and pending international or domestic patents. For more information about the company, please visit http://www.paragon-ip.com .

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies; the future success of our scientific studies; our ability to successfully develop products; rapid technological change in our markets; changes in demand for our future products; legislative, regulatory, and competitive developments; and general economic conditions. Our Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statements on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations, and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

For more information, please click here

Contacts:
Unidym, Inc.
Arthur L. Swift, CEO, 650-462-1935

or
Paragon Intellectual Properties
Dan Heilbrunn, Vice President of Marketing, 604-662-3589

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanotubes/Buckyballs

Materials for the next generation of electronics and photovoltaics: MacArthur Fellow develops new uses for carbon nanotubes October 21st, 2014

Special UO microscope captures defects in nanotubes: University of Oregon chemists provide a detailed view of traps that disrupt energy flow, possibly pointing toward improved charge-carrying devices October 21st, 2014

Imaging electric charge propagating along microbial nanowires October 20th, 2014

Beyond LEDs: Brighter, new energy-saving flat panel lights based on carbon nanotubes - Planar light source using a phosphor screen with highly crystalline single-walled carbon nanotubes (SWCNTs) as field emitters demonstrates its potential for energy-efficient lighting device October 14th, 2014

Nanomedicine

RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014

Sopping up proteins with thermosponges: Researchers develop novel nanoparticle platform that proves effective in delivering protein-based drugs October 22nd, 2014

Journal Nanotechnology Progress International (JONPI), 2014, Volume 5, Issue 1, pp 1-24 October 22nd, 2014

TARA Biosystems and Harris & Harris Group Form Company to Improve Safety and Efficacy of New Therapies October 22nd, 2014

Announcements

Advancing thin film research with nanostructured AZO: Innovnano’s unique and cost-effective AZO sputtering targets for the production of transparent conducting oxides October 23rd, 2014

Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014

RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014

Researchers patent a nanofluid that improves heat conductivity October 22nd, 2014

Patents/IP/Tech Transfer/Licensing

Researchers patent a nanofluid that improves heat conductivity October 22nd, 2014

Nanodevices for clinical diagnostic with potential for the international market: The development is based on optical principles and provides precision and allows saving vital time for the patient October 15th, 2014

Aculon Receives Patent for Application of Enhanced Bonding Layers on Titanium October 9th, 2014

harmaEngine will join Nanobiotix’ pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific: PharmaEngine to make milestone payment to Nanobiotix in October 2014 to recognize the value created October 8th, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE